Kodiak Sciences turns down $125M from Baker Bros Advisors as it pushes on with wet AMD, other eye drugs bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
News provided by
Share this article
Share this article
PALO ALTO, Calif., March 1, 2021 /PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2020. Our Phase 1b data show two in every three patients are on a 6-month or longer treatment free interval at Year 1 in each of the three major retinal vascular diseases after only three loading doses , said Victor Perlroth, MD, Chief Executive Officer of Kodiak. Importantly, the durability profile of KSI-301 is tied to strong efficacy improvements in all three diseases at Year 1. The treatment naïve wet AMD patients in our study achieved 20/40 vision on average at Year 1 and DME
How One Woman Turned a $40 Million Kuaishou Bet Into $12 Billion
Bloomberg 2/9/2021 Zheping Huang, Coco Liu and Peter Elstrom
(Bloomberg) In 2014, as their video app Kuaishou began to take off, Su Hua and his co-founders started looking for money to expand. They quickly got a proposal from Ruby Lu, a venture investor who had spotted them earlier as promising engineers and given them feedback on previous businesses.
But Lu’s proposal was trumped by a larger venture firm with a much higher offer, according to people familiar with the matter. She refused to concede. Lu pitched Su and his team that she would give them more than money, offering her personal engagement and the support of her partners at DCM Ventures. She won, even with a lower offer.
Last Friday, Kuaishou Technology started trading in Hong Kong after the biggest initial share sale for an internet company since Uber Technologies Inc in 2019.
Share this article
Share this article
PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition meeting.
Details of the presentation are as follows:
Title: KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases
Presenter: Diana V. Do, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine, Stanford, CA